Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

-Results -Compared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P<0.0001); MSbG (P<0.0001) and in SbG (P = 0.003). There were statistically significant differences in the symptom score at 30 th day therapy of the MG, MSbG and SbG groups (P = 0.03). There were no statistical differences between MSbG and MG symptom score at 30th day therapy (P = 0.9). Conclusions -The use of mesalazine alone, Saccharomyces boulardii alone or combined treatment with mesalasine and Saccaromyces boulardii improved IBS-D symptoms. The improvement of the symptom score was greater with mesalazine alone or combined with Sb as compared with Sb treatment alone. These preliminary results suggest that mezalazine may be useful in treatment of IBS-d patients, and warrant further larger studies. HEADINGS -Irritable bowel syndrome. Diarrhea. Mesalamine. Saccharomyces boulardii.

show abstract

“…No physical or laboratory findings are specific for IBS, and the diagnosis is, therefore, based on symptomatology (1) .…”

Section: Discussionmentioning

confidence: 99%

“…Since mucosal inflammation and imbalance in (1,3) . Saccharomyces boulardii, isolated from litchi fruit by Henri Boulard in the 1920s, belongs to the Saccharomyces genus, being commonly used in several food processes that produce beverages or require fermentation.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Boiocchi

Almeida

Leite

et al. 2013

Arq. Gastroenterol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a second small ( N = 61) study, patients meeting Rome III criteria for IBS with diarrhea, including 18 patients with postinfectious IBS, received mesalazine 800 mg 3 times daily for 30 days. Among patients with postinfectious IBS, there was a signifi cant reduction from baseline in total symptom scores, stool frequency, abdominal pain, and abdominal distension ( P < 0.0001 for all comparisons) ( 42 ). However, this study has some important limitations (open, noncomparative, and nonblinded), and the results should be confi rmed in other welldesigned investigations.…”

Section: Treatment Of Postinfectious Functional Gastrointestinal Disomentioning

confidence: 69%

Postinfectious Chronic Gut Dysfunction: From Bench to Bedside

Collins¹,

Chang²,

Mearin³

2012

Am J Gastroenterol Suppl

View full text Add to dashboard Cite

“…Bafutto et al [109] CT, IBS-D 800 mg tid, 30 days Significant improvement of total symptom score, inclusive of pain.…”

Section: Aminosalicylic Acid Agentsmentioning

confidence: 99%

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched, and despite a long journey for unraveling all the structures and the pathways involved, it still remains partially obscure. Inflammation was the first to be hypothesized as a potential pathway for the pathogenesis of IBS. It remains a keystone in the complex machinery of the pathogenesis that is currently considered multifactorial. Elucidating the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter, we review information regarding gut inflammation in IBS, underlining some of the newest data or the cornerstones. Additionally, our aim was also to review treatment currently available and future perspectives regarding anti-inflammatory treatments for IBS. Newer techniques allow detection and research of mediators involved in inflammation, as well as their potential role to be targeted by pharmacological agents. Recent data supports not only further research of the newer agents that are currently being developed but also some of the available ones that do not have sufficient evidence. Emerging therapies that target inflammation are under evaluation, in trials. A multidrug or a multidisciplinary approach needs to be considered in some cases that fail to respond to current treatment.

show abstract

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

Cited by 21 publications

References 26 publications

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome With Mesalazine and/or Saccharomyces Boulardii

Postinfectious Chronic Gut Dysfunction: From Bench to Bedside

Inflammation as a Potential Therapeutic Target in IBS

Contact Info

Product

Resources

About